Novartis AG (ADR)
General ticker "NVS" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $275.5B (TTM average)
Novartis AG (ADR) follows the US Stock Market performance with the rate: 21.3%.
Estimated limits based on current volatility of 0.7%: low 150.14$, high 152.22$
Factors to consider:
- Earnings expected soon, date: 2026-10-27 bmo
- Company pays dividends (annually): last record date 2026-03-11, amount 4.74$ (Y3.15%)
- Total employees count: 75267 (-0.8%) as of 2025
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [112.62$, 154.04$]
- 2026-12-31 to 2027-12-31 estimated range: [125.25$, 168.72$]
Financial Metrics affecting the NVS estimates:
- Positive: with PPE of 15.4 at the end of fiscal year the price was neutral
- Positive: 6.77 < Operating cash flow per share per price, % of 7.16
- Positive: 22.58 < Operating profit margin, % of 31.15
- Positive: 14.78 < Industry operating profit margin (median), % of 24.67
- Positive: 5.56 < Industry operating cash flow per share per price (median), % of 5.61
- Positive: -2.60 < Investing cash flow per share per price, % of -1.82
- Positive: Interest expense per share per price, % of 0.44 <= 0.75
- Positive: Industry inventory ratio change (median), % of 0.50 <= 1.15
- Positive: Industry earnings per price (median), % of 6.62 > 6.58
Short-term NVS quotes
Long-term NVS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $46,660.00MM | $51,722.00MM | $54,811.25MM |
| Operating Expenses | $36,891.00MM | $37,178.00MM | $37,737.26MM |
| Operating Income | $9,769.00MM | $14,544.00MM | $17,073.99MM |
| Non-Operating Income | $-646.00MM | $-904.00MM | $-638.25MM |
| Interest Expense | $876.12MM | $1,036.41MM | $1,187.05MM |
| R&D Expense | $11,371.00MM | $10,022.00MM | $10,741.73MM |
| Income(Loss) | $9,123.00MM | $13,640.00MM | $16,435.74MM |
| Taxes | $551.00MM | $1,701.00MM | $2,397.21MM |
| Net Income(Loss)* | $14,850.00MM | $11,941.00MM | $14,055.61MM |
| Stockholders Equity | $46,667.00MM | $44,046.00MM | $46,130.08MM |
| Inventory | $5,913.00MM | $5,723.00MM | $6,269.01MM |
| Assets | $99,945.00MM | $102,246.00MM | $115,569.20MM |
| Operating Cash Flow | $14,458.00MM | $17,619.00MM | $19,242.03MM |
| Capital expenditure | $2,753.00MM | $3,814.00MM | $1,555.93MM |
| Investing Cash Flow | $5,596.00MM | $-7,513.00MM | $-4,901.98MM |
| Financing Cash Flow | $-14,278.00MM | $-11,742.00MM | $-14,943.13MM |
| Earnings Per Share** | $7.15 | $5.92 | $7.25 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.